Dermapharm Holding SE: directors' dealings · Germany · BaFin

About Dermapharm Holding SE

Dermapharm Holding SE is a German-listed pharmaceutical and healthcare group traded on Xetra/Frankfurt (DAX/MDAX/SDAX), headquartered in Grünwald near Munich, Germany. Founded in 1991, the company has built an integrated business model spanning in-house development, manufacturing, quality management, logistics and distribution. From an equity research perspective, Dermapharm is best understood as a specialty healthcare platform focused on branded medicines and regulated consumer-health assets rather than a pure commodity generics player. The group states that it manufactures the large majority of its pharmaceutical portfolio internally, which is an important industrial and margin-supportive differentiator. Dermapharm’s operations are structured into three segments. “Branded pharmaceuticals” is the core segment and covers proprietary, branded medicines developed and commercialized by the group across therapeutic areas such as dermatology, allergy, pain, women’s health and other prescription/OTC niches. “Other healthcare products” includes food supplements, herbal medicines, cosmetics, medical devices, herbal extracts and medicinal cannabis. This segment has been expanded through international acquisitions, notably Arkopharma in France, Euromed in Spain, Montavit in Austria and Cernelle in Sweden. The third segment, “Parallel import business”, is led by axicorp and focuses on the parallel import of originator pharmaceuticals, a business that tends to be more sensitive to pricing spreads, reimbursement dynamics and portfolio optimization. Geographically, Dermapharm remains firmly anchored in Germany, its key industrial and commercial base, while also operating production, development and distribution sites across Europe, as well as in the United States and parts of Asia. The company emphasizes its broad footprint in Europe, which supports both commercial diversification and manufacturing resilience. Dermapharm also highlights a portfolio of more than 1,300 marketing authorizations and more than 380 active pharmaceutical ingredients in its core branded-pharmaceuticals and healthcare activities, reinforcing the depth of its product base and launch capabilities. Recent developments are notable. On 10 March 2026, Dermapharm published preliminary 2025 figures showing revenue of EUR 1,165.0 million, down modestly year on year, while adjusted EBITDA increased to EUR 324.8 million and the adjusted margin improved. The company also announced a public share buyback offer for up to 4.3 million shares at EUR 42.00 per share. This followed a 2025 trading year in which management consistently pointed to stable underlying profitability despite portfolio adjustments in parallel imports. For investors, the key appeal lies in a defensive healthcare profile, strong cash-generation characteristics, a meaningful branded-product platform and ongoing capital allocation discipline.